Titre:
  • A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Auteur:Green, M D; Koelbl, H; Baselga, J; Galid, A; Guillem, V; Gascon, P; Siena, S; Lalisang, R I; Samonigg, H; Clemens, Michael; Zani, V; Liang, B C; Renwick, Jennifer; Piccart-Gebhart, Martine; International Pegfilgrastim 749 Study Group,
Informations sur la publication:Annals of oncology, 14, 1, page (29-35)
Statut de publication:Publié, 2003-01
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Delayed-Action Preparations
Double-Blind Method
Doxorubicin -- administration & dosage
Doxorubicin -- adverse effects
Drug Administration Schedule
Female
Filgrastim -- administration & dosage
Filgrastim -- analogs & derivatives
Humans
Middle Aged
Neoplasm Staging
Neutropenia -- chemically induced
Neutropenia -- drug therapy
Neutrophils -- physiology
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Paclitaxel -- analogs & derivatives
Taxoids
Note générale:Clinical Trial
Clinical Trial, Phase III
Comment
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:pmid/12488289